Question 1

How do NK1 receptor antagonists prevent chemotherapy-induced nausea and vomiting?

Accepted Answer

NK1 receptor antagonists like aprepitant, netupitant, and rolapitant selectively bind to neurokinin-1 receptors in the brainstem, blocking substance P from activating these receptors. Chemotherapy stimulates the GI mucosa to release substance P, which crosses the blood-brain barrier and triggers vomiting. By preventing substance P binding, these antagonists effectively inhibit the delayed phase of chemotherapy-induced nausea and vomiting.

Question 2

What is the difference between acute and delayed phases of chemotherapy-induced nausea and vomiting?

Accepted Answer

The acute phase of chemotherapy-induced nausea and vomiting occurs within hours of chemotherapy treatment, while the delayed phase develops between two and five days post-treatment. NK1 receptor antagonists are particularly effective at inhibiting the delayed phase. Most anti-emetic drugs control the acute phase, but NK1 antagonists are combined with 5-HT3 antagonists and dexamethasone for comprehensive protection against both phases.

Question 3

Where are NK1 receptors located in the body?

Accepted Answer

Neurokinin-1 receptors are distributed across multiple sites including the gastrointestinal tract, vagal afferents, and key central nervous system regions. The central vomiting center and chemoreceptor trigger zone in the brainstem are particularly rich in NK1 receptors. This widespread distribution allows substance P to activate the vomiting reflex through multiple pathways during chemotherapy.

Question 4

What drug interactions should be monitored with NK1 receptor antagonists?

Accepted Answer

NK1 receptor antagonists are metabolized primarily through the liver's CYP3A4 pathway. This hepatic metabolism can suppress the metabolism of anti-cancer agents like docetaxel, paclitaxel, and imatinib, potentially increasing their blood concentrations. Clinicians must monitor patients carefully when combining NK1 antagonists with these chemotherapy drugs to avoid adverse effects from elevated drug levels.

Question 5

What are the common adverse effects of NK1 receptor antagonists?

Accepted Answer

Common adverse effects of NK1 receptor antagonists include fatigue, abdominal pain, diarrhea, and hiccups. Neutropenia, a decrease in white blood cells, occurs uncommonly but requires monitoring. These side effects are generally manageable and less severe than the nausea and vomiting they prevent, making them valuable options for patients undergoing chemotherapy.

Question 6

Why is substance P significant in chemotherapy-induced nausea and vomiting?

Accepted Answer

Substance P is a neuropeptide released by enterochromaffin cells in the gastrointestinal tract when chemotherapy agents stimulate the GI mucosa. This neuropeptide crosses the blood-brain barrier and binds to NK1 receptors in the vomiting center and chemoreceptor trigger zone, triggering the nausea and vomiting response. Understanding this mechanism led to the development of NK1 antagonists that block substance P binding.

Question 7

How do NK1 antagonists fit into a comprehensive anti-emetic strategy?

Accepted Answer

NK1 receptor antagonists are typically used alongside other anti-emetic medications for optimal chemotherapy-induced nausea and vomiting prevention. They are combined with 5-HT3 antagonists, which target the acute phase, and dexamethasone, a corticosteroid. This multi-drug approach addresses different mechanisms of nausea and vomiting, with NK1 antagonists specifically targeting the delayed phase that occurs days after treatment.

בחילות והקאות הנגרמות מכימותרפיה: נוירוקינין-1

Browse More Videos